Advertisement

Clinical trial of BRL 1241 (Celbenin)

  • Douglas Montgomery
Article
  • 31 Downloads

Conclusion

Celbenin has proved its worth in other cases in the Meath Hospital as well, but enough has been exemplified to show its major preeminence in cases where other drugs would fail. Most important of all, Celbenin may be regarded as unlikely to produce resistant strains of staphylococcus aureus and therefore will continue as a permanent weapon against a foe that demands respect.

References

  1. Knudsen, E. T. and Rolinson, G. N. (1960).Brit. Med. J., ii, 700.CrossRefGoogle Scholar
  2. Rolinson, Stevens,et al. (1960).Lancet, ii, 564.CrossRefGoogle Scholar
  3. Brown, D. M. and Acred, P. (1960). Ibid.,, 568.CrossRefGoogle Scholar
  4. Branch, Rodgeret al. (1960).Canad., M. A. J., 83, 991.Google Scholar
  5. Editorial, (1961).Brit. Med. J., i, 886.Google Scholar
  6. Douthwaite, A. H. (1961).Practitioner, 186, 511.PubMedGoogle Scholar
  7. Lowbury, Lillyet al. (1961).Lancet, i, 1318.CrossRefGoogle Scholar
  8. Douthwaite, Traffordet al. (1961).Brit. Med. J., ii, 6.CrossRefGoogle Scholar
  9. Harding, J. W. and Thompson, R. E. M. (1961).Postgrad. Med. J., 1961,37, 485.PubMedCentralPubMedCrossRefGoogle Scholar
  10. Clinical Staff Conference (1961).Antibiotics and Chemotherapy, ii, No. 9, 537–554.Google Scholar

Copyright information

© Springer 1962

Authors and Affiliations

  • Douglas Montgomery
    • 1
  1. 1.Meath HospitalDublin

Personalised recommendations